Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inhaled medicines
Pharma
AstraZeneca caps out-of-pocket inhaler costs at $35 in the US
At a critical moment for the U.S. inhaler market, AstraZeneca is following its peer Boehringer Ingelheim and taking a step to boost patient access.
Fraiser Kansteiner
Mar 18, 2024 11:02am
Celltrion races inhaled COVID-19 antibody therapy into phase 3
Feb 7, 2022 7:30am
Aerami is jumping on the SPAC bandwagon in bid to go public
Dec 14, 2021 3:40pm
CanSino, Aerogen team up on inhalable COVID-19 vaccine hopeful
Dec 13, 2021 4:40pm
Omicron spurs Celltrion to speed development of nebulized drug
Nov 30, 2021 9:25am
FDA starts pilot after J&J makes case for delivery excipients
Sep 14, 2021 7:55am
